Inclusion Criteria:

- Life expectancy of at least 12 weeks

- Clinical, radiographic, or pathologic diagnosis of metastatic renal cell carcinoma
(RCC). All renal cell histologies are allowed

- Acceptable surgical risk in the judgment of the study investigator and consulting
urological surgeon

- At least one uni-dimensional measurable lesion outside the planned nephrectomy
specimen

- Patients who have an ECOG performance status of 0 or 1

Exclusion Criteria:

- History of bleeding diathesis or unexpected surgical bleeding

- Patients currently receiving treatment with or having a requirement for therapeutic
anticoagulation

- Prior therapy for RCC. Palliative radiation therapy for painful or unstable bone
metastases is permitted provided that there is measurable metastatic disease outside
the radiation field

- Known history of HIV infection

- Symptomatic metastatic brain or meningeal tumors, unless the patient is > 6 months
from definitive therapy, has a CT or MRI scan within 6 weeks of study entry negative
for brain metastases and is clinically stable with respect to the tumor at the time
of study entry